Abstract | BACKGROUND: OBJECTIVE: METHODS: Oral methotrexate, at an initial dosage of 5 mg/wk, was given to 11 consecutive patients older than 70 years of age who were not responding to potent topical steroids. If the response was insufficient, the methotrexate dose was increased by 2.5 mg/wk to a maximum of 12.5 mg/wk. RESULTS: All patients responded with a marked and rapid decrease in disease activity. The disease was controlled in the majority of patients (8 of 11) with 5 to 7.5 mg of methotrexate per week. Three patients required a weekly dose of 10 to 12.5 mg. At 24 months of follow-up 7 patients were in complete remission and did not require methotrexate. CONCLUSION: Our study suggests that low-dose oral pulse methotrexate constitutes an effective therapeutic alternative in elderly patients with generalized bullous pemphigoid.
|
Authors | J D Heilborn, M Ståhle-Bäckdahl, F Albertioni, I Vassilaki, C Peterson, E Stephansson |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 40
Issue 5 Pt 1
Pg. 741-9
(May 1999)
ISSN: 0190-9622 [Print] United States |
PMID | 10321603
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dermatologic Agents
- Glucocorticoids
- Immunosuppressive Agents
- Prednisone
- Methotrexate
|
Topics |
- Administration, Oral
- Aged
- Aged, 80 and over
- Anemia
(chemically induced)
- Dermatologic Agents
(administration & dosage, adverse effects, analysis, blood, therapeutic use)
- Exudates and Transudates
(chemistry)
- Female
- Follow-Up Studies
- Glucocorticoids
(administration & dosage, therapeutic use)
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects, analysis, blood, therapeutic use)
- Male
- Methotrexate
(administration & dosage, adverse effects, analysis, blood, therapeutic use)
- Pemphigoid, Bullous
(drug therapy, pathology)
- Prednisone
(administration & dosage, therapeutic use)
- Remission Induction
- Safety
|